Kexing Biopharm

Kexing Biopharm (Stock Code: 688136) is an innovative biopharmaceutical enterprise mainly engaged in the R&D, production, and sales integration of recombinant protein drugs and microecological preparations. It focuses on treatment areas such as antiviral, oncology and immunology, hematology, gastroenterology, and degenerative diseases, building cutting-edge biotechnology platforms for new proteins, new antibodies, and nucleic acid drugs. It adheres to a platform-based development model driven by "innovation + internationalization" while exploring the wide application of biotechnology in the field of healthcare, actively nurturing and incubating new industries, committed to becoming a leader in high-quality biological drugs and serving patients worldwide. Its main products include recombinant protein drugs "Human Erythropoietin (Epoetin Alpha, brand name: Yipuding)", "Human Interferon α1b (brand name: Sai Ruojin)", "Human Granulocyte Colony-Stimulating Factor (brand name: Bai Texi)", microecological preparation drug "Clostridium Butyricum Combined Live Bacteria (brand name: Chang Le Kang)", exclusive traditional Chinese medicine "Ke Huang Capsules", chemical drug "Entecavir (brand name: Sai Gan Su)", and imported advanced complex formulations such as "Albumin-bound Paclitaxel (brand name: Bai Rui Ning)", monoclonal antibody drugs "Infliximab (brand name: Leiting)" and "Bevacizumab". In recent years, Kexing Biopharm has experienced continuous rapid business growth and has become a leading company in recombinant protein drugs. Its core products rank among the top domestic varieties in China, covering nearly 20,000 terminals across all provinces and regions in China, including nearly 7,000 tertiary hospitals, and have gained market access and achieved sales in nearly 40 countries and regions globally, including Brazil, the Philippines, and Indonesia. After more than two decades of pharmaceutical R&D and industrial technology accumulation, Kexing Biopharm has built a complete drug R&D innovation system, covering the entire process from drug discovery, pharmaceutical research, preclinical studies, clinical trials to industrialization. It possesses three major technical systems: prokaryotic cell technology, eukaryotic cell technology, and microecological live bacteria technology, successfully constructing multiple leading domestic and international technology platforms such as a recombinant protein secretion expression technology platform, a recombinant protein drug industrialization technology platform, a long-acting recombinant protein technology platform, a microecological preparation R&D and industrialization technology platform, a bacterial strain technology platform, an antibody technology platform, and a vector vaccine technology platform. The company's technology center was recognized as a "Provincial Enterprise Technology Center of Shandong Province" in 2017, a "Jinan Protein Drug Engineering Laboratory" in 2018, and a "Guangdong Gene Engineering Recombinant Protein Drug Engineering Technology Center", a "Shandong Protein Drug Engineering Laboratory", and a "Shenzhen Postdoctoral Innovation Practice Base" in 2020. The company has obtained more than 40 patents and has over 10 ongoing R&D projects. In the future, Kexing Biopharm will uphold the mission of "Refined pharmaceuticals, refined medication, safeguarding health," serving patients with biotechnology and striving to become a leader in high-quality biological drugs.